Biofons Celiac Disease Panel Print

Clinical symptoms and basis of diagnostics

Coeliac disease (CD) and Dermatitis Herpetiformis (DH) are autoimmune diseases with known environmental triggers and a strong genetic component.  The external trigger is ingested wheat gluten or related proteins from rye, barley and possibly oats.  CD is a multigenic disorder with a strong HLA association.  HLA-DQ2 and DQ8 confer susceptibility together with, as yet unidentified, gene loci.  Expression of HLA-DQ2 and DQ8 molecules that present gliadin-derived peptides to CD4 T cells is necessary but not sufficient to develop CD.

Read More

NA1000 Biofons Anti-Gliadin IgA
The Biofons Anti-gliadin IgA kit is intended for the determination of human anti-gliadin IgA in serum.  The Biofons Anti-gliadin IgA and IgG kits have been designed for use as sensitive screening tests for jejunal biopsy in patients with suspected Celiac disease.  Monitoring the disappearance of gliadin antibodies during a gluten-free diet can be used to indicate successful elimination of gluten from the diet.  These tests are also useful in the screening of dermatitis herpetiformis.  The protocol used is the same as with Anti-Gliadin IgG ELISA and all the other Biofons Celiac Disease Panel ELISA kits, which make these tests easy to perform at the same time.  Package insert
NG1000 Biofons Anti-Gliadin IgG
The Biofons Anti-gliadin IgG kit is intended for the determination of human anti-gliadin IgG in serum.  Biofons Anti-gliadin IgA and IgG kits have been designed for use as sensitive screening tests for jejunal biopsy in patients with suspected Celiac disease.  Monitoring the disappearance of gliadin antibodies during a gluten-free diet can be used to indicate successful elimination of gluten from the diet.  These tests are also useful in the screening of dermatitis herpetiformis.  Gliadin antibodies are also formed in some other conditions leading to increased absorption of macromolecules in the intestine, for example: Cow's milk allergy, Crohn's disease and other inflammatory intestinal diseases.  Therefore the diagnosis of Celiac disease cannot be based solely on gliadin antibodies.  An intestinal biopsy must always be taken to confirm the diagnosis. Since IgA deficient subjects have a 10 times higher incidence of Celiac disease, and the prevalence of serum IgA deficiency is 1:400, it is highly recommended that in addition to IgA antibodies, IgG antibodies to gliadin should also be screened in patients with suspected Celiac disease.  The protocol used is same as with Anti-Gliadin IgG ELISA and all the other Biofons Celiac Disease Panel ELISA kits, which make these tests easy to perform at the same time.  Package insert
RTA4000 Biofons Anti-Transglutaminase IgA
The Biofons Anti-Transglutaminase IgA kit is intended for the determination of human anti-tissue transglutaminase IgA in serum.  The kit has been designed for use as a sensitive screening test for jejunal biopsy in patients with suspected Celiac disease.  This test is also useful in the screening of dermatitis herpetiformis.  The protocol used is the same as with Anti-Gliadin IgA and IgG ELISA tests, which make these tests easy to perform at the same time as a complete Celiac panel.  Package insert
RTG4000 Biofons Anti-Transglutaminase IgG
The Biofons tTG IgG kit is an enzyme-linked immunosorbent assay (ELISA) for the qualitative/semi quantitative detection of IgG class anti-tissue transglutaminase antibodies (tTG IgG) in human serum.  The test is intended to be used as a screening test for jejunal biopsy in IgA deficient patients with suspected Celiac disease.  Since IgA deficient subjects have a 10 times higher incidence of Celiac disease, and the prevalence of serum IgA deficiency is 1:400, it is highly recommended that in addition to IgA antibodies, IgG antibodies to tTG should also be screened for in patients with suspected Celiac disease.  Package Insert
SC3000 Biofons Anti-Endomysial (hUC) IgA (available also as Monkey)
Indirect fluorescent assay (IFA) for anti-endomysial antibodies has proved to be a good method to screen for Celiac disease.  Endomysial antibodies of the IgA subclass (IgA EmA) react with the reticulin component of the endomysium of the smooth muscle in primate oesophagus tissue.  These antibodies can be found in 60-70% of patients with Dermatitis herpetiformis (DH) on a non-restricted diet and in almost 100% of patients with Celiac disease (CD) and gluten-sensitivity enteropathy with partial or subtotalling villous atrophy.  There is a small percentage of IgG EmA that will show negative IgA when screened.  A negative result exhibited by a patient with overt clinical symptoms may need to be considered for IgG testing.

Performance of an anti-Gliadin test is recommended in order to reach the maximum specificity of the test.  It has been demonstrated that serum IgA endomysial antibodies were found in the majority (87%) of patients with untreated Celiac disease and approximately 70% of anti-Gliadin (IgA AGA) positive patients.  The R1 anti-Reticulin (R1-ARA) appears to be a less reliable marker with less than 50% being positive.  These findings were based on the same patient population.  It should be noted that a strict adherence to a gluten-free diet will greatly affect the antibody results in most patients.  IgA AGA and R1-ARA will normally disappear after one year while IgA EmA may persist at a lower titer.  In this way, the test may have prognostic value in monitoring strict adherence to diet.  Package Insert
Last Updated on Wednesday, 12 May 2010 10:40